Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel nanoparticles
- Development stage
- Preclinical
- Lead developer
- Optimum Therapeutics
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
Paclitaxel nanoparticles (PNP) is an investigational nanoparticle formulation of the taxane chemotherapy agent paclitaxel, developed by Optimum Therapeutics, LLC. It is designed for intravenous administration to treat solid tumors. The formulation is intended to be used in conjunction with the company's proprietary "Tumor Priming Technology," which aims to improve the delivery and penetration of nanomedicines into solid tumors by reducing interstitial fluid pressure. Paclitaxel itself is a microtubule-stabilizing agent that binds to the beta-subunit of tubulin, promoting microtubule assembly and preventing depolymerization. This action leads to mitotic arrest and subsequent apoptosis of cancer cells. The nanoparticle formulation is designed to enhance the pharmacokinetic profile and tumor accumulation of paclitaxel compared to standard formulations.
- Other names
- PNPpaclitaxel nanoparticlesPNP-paclitaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on paclitaxel nanoparticles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel nanoparticles.